Research progress on effects of traditional Chinese medicine on myocardial ischemia–reperfusion injury: A review

Na Xing; Na Xing; Xiao-Tong Long; Xiao-Tong Long; Hui-Juan Zhang; Hui-Juan Zhang; Li-Dan Fu; Li-Dan Fu; Jian-Yuan Huang; Jian-Yuan Huang; Abdallah Iddy Chaurembo; Abdallah Iddy Chaurembo; Abdallah Iddy Chaurembo; Francis Chanda; Francis Chanda; Francis Chanda; Yun-Jing Xu; Yun-Jing Xu; Yun-Jing Xu; Chi Shu; Chi Shu; Kai-Xuan Lin; Kai-Xuan Lin; Ke Yang; Ke Yang; Han-Bin Lin; Han-Bin Lin; Han-Bin Lin

doi:10.3389/fphar.2022.1055248

Frontiers in Pharmacology (Dec 2022)

Research progress on effects of traditional Chinese medicine on myocardial ischemia–reperfusion injury: A review

Na Xing,
Na Xing,
Xiao-Tong Long,
Xiao-Tong Long,
Hui-Juan Zhang,
Hui-Juan Zhang,
Li-Dan Fu,
Li-Dan Fu,
Jian-Yuan Huang,
Jian-Yuan Huang,
Abdallah Iddy Chaurembo,
Abdallah Iddy Chaurembo,
Abdallah Iddy Chaurembo,
Francis Chanda,
Francis Chanda,
Francis Chanda,
Yun-Jing Xu,
Yun-Jing Xu,
Yun-Jing Xu,
Chi Shu,
Chi Shu,
Kai-Xuan Lin,
Kai-Xuan Lin,
Ke Yang,
Ke Yang,
Han-Bin Lin,
Han-Bin Lin,
Han-Bin Lin

Affiliations

Na Xing: Zhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China
Na Xing: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
Xiao-Tong Long: Zhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China
Xiao-Tong Long: Department of Physiology, University of Toronto, Toronto, ON, Canada
Hui-Juan Zhang: Zhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China
Hui-Juan Zhang: College of Pharmacy, Zunyi Medical University, Zunyi, Guizhou, China
Li-Dan Fu: Zhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China
Li-Dan Fu: College of Pharmacy, Zunyi Medical University, Zunyi, Guizhou, China
Jian-Yuan Huang: Zhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China
Jian-Yuan Huang: College of Pharmacy, Southern Medical University, Guangzhou, Guangdong, China
Abdallah Iddy Chaurembo: Zhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China
Abdallah Iddy Chaurembo: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
Abdallah Iddy Chaurembo: University of Chinese Academy of Sciences, Beijing, China
Francis Chanda: Zhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China
Francis Chanda: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
Francis Chanda: University of Chinese Academy of Sciences, Beijing, China
Yun-Jing Xu: Zhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China
Yun-Jing Xu: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
Yun-Jing Xu: University of Chinese Academy of Sciences, Beijing, China
Chi Shu: Zhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China
Chi Shu: College of Food Science, Shenyang Agricultural University, Shenyang, Liaoning, China
Kai-Xuan Lin: Department of Cardiology, Zhongshan Hospital Affiliated with Guangzhou University of Chinese Medicine (Zhongshan Hospital of Traditional Chinese Medicine), Zhongshan, Guangdong, China
Kai-Xuan Lin: Guangzhou University of Chinese Medicine, Guangzhou, China
Ke Yang: Zhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China
Ke Yang: 0College of Life Sciences, China Jiliang University, Hangzhou, Zhejiang, China
Han-Bin Lin: Zhongshan Institute for Drug Discovery, SIMM CAS, Zhongshan, Guangdong, China
Han-Bin Lin: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
Han-Bin Lin: University of Chinese Academy of Sciences, Beijing, China

DOI: https://doi.org/10.3389/fphar.2022.1055248
Journal volume & issue: Vol. 13

Abstract

Read online

Ischemic heart disease (IHD) is a high-risk disease in the middle-aged and elderly population. The ischemic heart may be further damaged after reperfusion therapy with percutaneous coronary intervention (PCI) and other methods, namely, myocardial ischemia–reperfusion injury (MIRI), which further affects revascularization and hinders patient rehabilitation. Therefore, the investigation of new therapies against MIRI has drawn great global attention. Within the long history of the prevention and treatment of MIRI, traditional Chinese medicine (TCM) has increasingly been recognized by the scientific community for its multi-component and multi-target effects. These multi-target effects provide a conspicuous advantage to the anti-MIRI of TCM to overcome the shortcomings of single-component drugs, thereby pointing toward a novel avenue for the treatment of MIRI. However, very few reviews have summarized the currently available anti-MIRI of TCM. Therefore, a systematic data mining of TCM for protecting against MIRI will certainly accelerate the processes of drug discovery and help to identify safe candidates with synergistic formulations. The present review aims to describe TCM-based research in MIRI treatment through electronic retrieval of articles, patents, and ethnopharmacology documents. This review reported the progress of research on the active ingredients, efficacy, and underlying mechanism of anti-MIRI in TCM and TCM formulas, provided scientific support to the clinical use of TCM in the treatment of MIRI, and revealed the corresponding clinical significance and development prospects of TCM in treating MIRI.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords